

VIVALIS ANNOUNCES THE FILING OF ITS SECOND ANNUAL REGISTRATION DOCUMENT

Nantes (France) – April 27, 2009 – VIVALIS announces the filing of its second Registration Document under the number R.09-028 dated April, 24 2009, with the Autorité des Marchés Financiers (« AMF »).

The registration document is available free of charge at VIVALIS' head office, 6, rue Alain Bombard, 44821 Saint-Herblain cedex, FRANCE and in electronic form on the company's web site (www.vivalis.com) and on the web site of the AMF (www.amf-france.org).

Next financial press release:

29 April 2009, after NYSE Euronext market closing: 2009 first-quarter sales

About VIVALIS (www.vivalis.com)

VIVALIS (NYSE - Euronext: VLS) is a biopharmaceutical company that provides to the pharmaceutical industry innovative cell-based solutions for the manufacture of vaccines and proteins, and develops drugs to prevent and treat viral diseases. VIVALIS' know-how and proprietary technologies are commercially exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EB66[®] cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of viral vaccines. VIVALIS receives upfront fees, milestone payments and royalties on its licensees' net sales.
2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses to pharmaceutical and biotechnology companies its EB66[®] cell line for the production of recombinant proteins. VIVALIS receives upfront fees, milestone payments and royalties on its licensees' net sales.
3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (Hepatitis C).

Based in Nantes (France), VIVALIS was created in 1999 by Group Grimaud (1,450 employees), the n² group worldwide in animal genetic breeding. VIVALIS has established more numerous partnerships with worldwide leaders in the sector, as Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Kaketsuken, Merial, SAFB Biosciences. VIVALIS is a member of the French Atlantic Biotherapies cluster.

VIVALIS

Listed on Euronext Paris – Compartment C of NYSE Euronext
Reuters: VLS.PA – Bloomberg: VLS FP
Member of NYSE Euronext's Next Biotech index



Investor Relations:

VIVALIS

Franck Grimaud, CEO
Email: investors@vivalis.com

NewCap.

Financial communication Agency
Steve Grobet / Emmanuel Huynh
Tel.: +33 (0) 1 44 71 94 91
Email: vivalis@newcap.fr